5th European Roundtable Meeting Report just released

Group photo of participants of 5th ERTM
20 June 2018

On 4 May 2018, participants from European organisations met in Berlin for the fifth in a series of European Roundtable Meetings focussing sharing best practice for improvement of cancer care.

The 2018 roundtable focused discussions around the interplay between basic cancer research, early phase clinical studies and large phase III trials and particularly, asking the question: What next to addressing the challenge of translating research findings in selected patient populations to routine use for all patients?

Start of 5th ERTM with agenda presentation by Prof. Dr Olaf Ortmann

Organised in collaboration between the German Cancer Society (DKG – Deutsche Krebsgesellschaft)and the Union for International Cancer Control (UICC), the event included representatives from the following organisations:

  • Association of European Cancer Leagues, Europe
  • The Cyprus Association of Cancer Patients and Friends, Nicosia, Cyprus
  • European Commission, Luxembourg
  • National Institute of Public Health, Ljubljana, Slovenia
  • European Partnership for Action Against Cancer / Catalonian Cancer Strategy, Spain
  • Cancer Center Karolinska, Stockholm, Sweden
  • Union for International Cancer Control (UICC), Global
  • Erasmus MC Rotterdam, The Netherlands
  • NHS England / The Christie NHS Foundation Trust, Manchester, United Kingdom
  • German Cancer Society, Berlin, Germany
  • The University Tumor Centre Jena, Germany
  • German Tumor Centres Work Group, Berlin, Germany
  • German Cancer Research Center (DKFZ), Germany
  • Martin-Luther University Halle-Wittenberg, Halle, Germany
  • University Medical Center Regensburg, Caritas-Hospital St. Josef, Regensburg, Germany
  • Haus der Krebsselbsthilfe Bundesverband e.V., Bonn, Germany

The keynote presentations framed the issue from three perspectives: that of patient advocates, a state of the art comprehensive cancer campus in the United Kingdom (UK) and a German national White Paper which proposes a role for translational cancers centres to respond to this deficit in health care processes. Participants then deepened discussion of common challenges and the need to shape a future model that facilitates more rapid uptake of innovation into routine cancer care, harnesses clinical data to drive basic research and also generates new hypotheses for improvement of standards of care.

Last update: 
Friday 7 June 2019
Share